| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Trial |
It has been postulated that hypertonic saline (HS) might impair the antimicrobial effects of defensins within the airways. Alternative non-ionic osmotic agents such as mannitol may thus be preferable to HS in promoting bronchial mucus clearance (BMC) in patients with cystic fibrosis (CF). This study reports the effect of inhalation of another osmotic agent, dry powder Mannitol (300 mg), compared with its control (empty capsules plus matched voluntary cough) and a 6% solution of HS on BMC in 12 patients with cystic fibrosis (CF). Mucus clearance was measured using a radioaerosol/gamma camera technique. Post-intervention clearance was measured for 60 min, followed by cough clearance for 30 min. Neither mannitol nor HS improved BMC during the actual intervention period compared with their respective controls. However during the post-intervention measurement there was a significant improvement in BMC for both the mannitol (8.7+/-3.3% versus 2.8+/-0.7%) and HS (10.0+/-2.3% versus 3.5+/-0.8%). There was also a significant improvement in cough clearance with the Mannitol (9.7+/-2.4%) compared with its control (2.5+/-0.8%). Despite premedication with a bronchodilator, a small fall in forced expiratory volume in one second (FEV1) was seen immediately after administration of both the mannitol (7.3+/-2.5%) and HS (5.8+/-1.2%). Values of FEV1 returned to baseline by the end of the study. Inhaled mannitol is a potential mucoactive agent in cystic fibrosis patients. Further studies are required to establish the optimal dose and the long-term effectiveness of mannitol.
This article has been cited by other articles:
|
|
 |
|
  S. J. Bartholdson, A. R. Brown, B. R. Mewburn, D. J. Clarke, S. C. Fry, D. J. Campopiano, and J. R. W. Govan Plant host and sugar alcohol induced exopolysaccharide biosynthesis in the Burkholderia cepacia complex Microbiology, August 1, 2008; 154(8): 2513 - 2521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jaques, E. Daviskas, J. A. Turton, K. McKay, P. Cooper, R. G. Stirling, C. F. Robertson, P. T. P. Bye, P. N. LeSouef, B. Shadbolt, et al. Inhaled Mannitol Improves Lung Function in Cystic Fibrosis Chest, June 1, 2008; 133(6): 1388 - 1396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Donaldson, T. E. Corcoran, B. L. Laube, and W. D. Bennett Mucociliary Clearance as an Outcome Measure for Cystic Fibrosis Clinical Research Proceedings of the ATS, August 1, 2007; 4(4): 399 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Grasemann, F. Stehling, H. Brunar, R. Widmann, T. W. Laliberte, L. Molina, G. Doring, and F. Ratjen Inhalation of Moli1901 in Patients With Cystic Fibrosis Chest, May 1, 2007; 131(5): 1461 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Levin, S. Sullivan, D. Nielson, B. Yang, W. E. Finkbeiner, and A. S. Verkman Hypertonic Saline Therapy in Cystic Fibrosis: EVIDENCE AGAINST THE PROPOSED MECHANISM INVOLVING AQUAPORINS J. Biol. Chem., September 1, 2006; 281(35): 25803 - 25812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Bolser Cough Suppressant and Pharmacologic Protussive Therapy: ACCP Evidence-Based Clinical Practice Guidelines Chest, January 1, 2006; 129(1_suppl): 238S - 249S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. McShane, J.C. Davies, T. Wodehouse, A. Bush, D. Geddes, and E.W.F.W. Alton Normal nasal mucociliary clearance in CF children: evidence against a CFTR-related defect Eur. Respir. J., July 1, 2004; 24(1): 95 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.C. Boucher New concepts of the pathogenesis of cystic fibrosis lung disease Eur. Respir. J., January 1, 2004; 23(1): 146 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.F. Joos and B. O'Connor Indirect airway challenges Eur. Respir. J., June 1, 2003; 21(6): 1050 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mandelberg, G. Tal, M. Witzling, E. Someck, S. Houri, A. Balin, and I. E. Priel Nebulized 3% Hypertonic Saline Solution Treatment in Hospitalized Infants With Viral Bronchiolitis Chest, February 1, 2003; 123(2): 481 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Daviskas, S.D. Anderson, S. Eberl, H-K. Chan, I.H. Young, and J.P. Seale Effects of terbutaline in combination with mannitol on mucociliary clearance Eur. Respir. J., December 1, 2002; 20(6): 1423 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Sarrell, G. Tal, M. Witzling, E. Someck, S. Houri, H. A. Cohen, and A. Mandelberg Nebulized 3% Hypertonic Saline Solution Treatment in Ambulatory Children With Viral Bronchiolitis Decreases Symptoms Chest, December 1, 2002; 122(6): 2015 - 2020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C F Robertson How do we choose a therapeutic regimen in cystic fibrosis? Thorax, October 1, 2002; 57(10): 839 - 840. [Full Text] [PDF]
|
|
|
|
|
|
P.G. Middleton, K.A. Pollard, and J.R. Wheatley Hypertonic saline alters ion transport across the human airway epithelium Eur. Respir. J., February 1, 2001; 17(2): 195 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Daviskas, S. D. Anderson, S. Eberl, H-K. Chan, and I. H. Young The 24-h Effect of Mannitol on the Clearance of Mucus in Patients With Bronchiectasis Chest, February 1, 2001; 119(2): 414 - 421. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
